New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:35 EDTADXSAdvaxis receives notice of allowance for 2 patent applications
Advaxis has received notice of allowance from the U.S. Patent and Trademark Office on two patents covering the composition and methods of use for ADXS-cHER2. Advaxis is developing ADXS-cHER2 to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer, breast cancer, esophageal, and gastric cancer. Advaxis plans to initiate a Phase 1 trial with ADXS-cHER2 in pediatric osteosarcoma, for which it received Orphan Drug Designation, and is pursuing early development clinical collaborations for breast, esophageal and gastric cancers.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
17:03 EDTADXSAdvaxis files to sell $200M of common stock
April 13, 2015
08:43 EDTADXSAdvaxis price target raised to $25 from $14 at H.C. Wainwright
Subscribe for More Information
April 8, 2015
16:22 EDTADXSOn The Fly: Closing Wrap
Subscribe for More Information
07:33 EDTADXSAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
April 6, 2015
07:34 EDTADXSAdvaxis, RTOG Foundation collaborate on Phase 2/3 trial of ADXS-HPV
Advaxis announced that it is entering into a clinical trial collaboration agreement with the Radiation Therapy Oncology Group, or RTOG, Foundation to evaluate the safety and efficacy of Advaxis's lead cancer immunotherapy, ADXS-HPV, in a pivotal Phase 2/3 anal cancer trial, which will be run by NRG Oncology. ADXS-HPV is an investigational Lm-LLO immunotherapy bioengineered to generate an immune response to the HPV-associated tumor specific oncogene. Under the proposed collaboration, RTOG Foundation, through its partnership with NRG Oncology, will conduct an adequate and well-controlled Phase 2/3 clinical trial of concurrent chemotherapy of mitomycin C/5FU and radiation therapy, or CCRT, compared to CCRT combined with ADXS-HPV in the adjuvant treatment of high-risk locally advanced anal cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use